1. Japan Stocks

  2. •

    Consumer Defensive

  3. •

    Packaged Foods
AFC-HD AMS Life Science Co., Ltd.

AFC-HD AMS Life Science Co., Ltd.

2927.T
AFC-HD AMS Life Science Co., Ltd.JP flagTokyo Stock Exchange
858.00
JPY
- -
- -
12.49BMarket Cap
AFC-HD AMS Life Science Co., Ltd.
2927.T
(Tokyo Stock Exchange)

Recent

price

858.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1,211.35
1,229.69
1,241.16
1,208.22
1,155.74
1,205.69
1,209.37
1,250.48
1,249.68
1,155.66
1,124.83
1,602.12
1,638.55
1,821.4
2,150.4
2,321.45
- -
Revenue per Share
16.35
41.13
47.74
48.14
23.82
50.64
40.47
38.48
58.28
55.7
48.12
107.12
52.33
78.51
89.2
102.98
- -
Basic EPS, GAAP
-14.63
-111.22
78.87
89.88
55.88
50.12
57.13
-26.95
53.19
41.61
65.26
149.74
38.03
-76.5
-132.98
-124.55
- -
Free Cash Flow per Basic Share
9.97
9.97
14.9
10.03
14.93
9.95
14.89
14.95
14.32
19.92
24.9
22.38
30.03
27.42
29.84
30.88
- -
Dividend per Share
323.89
355.36
388
427.1
436.37
474.19
494.13
517.17
596.83
572.09
595.21
684.21
712.52
763.42
822.59
893.08
- -
Book Value per Share
408.38
445.1
482.99
526.84
549.27
588.51
601.55
624.4
756.17
708.29
732.46
788.47
781.98
838.53
815.11
937.07
- -
Tangible Book Value per Share
12
12
12
12
12
12
12
12
13
14
14
14
14
14
14
14
- -
Basic Weighted Avg Shares
14,449
14,654
14,795
14,366
13,728
14,415
14,631
15,142
15,796
16,253
15,819
22,368
23,025
25,579
30,185
32,655
23,399
Sales/Revenue/Turnover
5.31
6.99
4.81
6.28
4.11
6.6
6.09
7.06
6.48
6.04
6.91
10.04
4.41
6.4
6.35
7.38
6.14
Operating Margin (%)
431
364
730
598
508
439
396
384
437
473
509
649
1,007
984
1,086
1,397
- -
Depreciation Expense
195
490
569
572
283
606
490
466
737
783
677
1,496
735
1,103
1,252
1,449
934
Net Income, GAAP
71.5
47.23
41.14
41.4
42.75
37.22
35.65
26.9
25.26
28.21
32.62
30.7
40.3
28.42
34.82
33.27
35.41
Effective Tax Rate (%)
1.35
3.34
3.85
3.98
2.06
4.2
3.35
3.08
4.66
4.82
4.28
6.69
3.19
4.31
4.15
4.44
3.99
Profit Margin (%)
992
1,656
1,260
1,780
1,484
2,152
2,231
560
2,881
2,733
3,805
4,050
3,907
5,021
4,472
-3,667
-17,027
Working Capital
2,457
4,470
3,217
3,104
2,342
2,257
1,933
505
1,317
486
1,082
9,691
10,136
11,320
13,293
5,475
- -
LT Debt
5,091
5,458
5,849
6,324
6,570
7,089
7,373
7,664
9,653
10,110
10,464
12,661
12,445
13,157
13,958
15,200
- -
Total Equity
2
4.35
3.06
3.88
2.44
4.63
4.51
6.16
5.67
4.94
5.07
7.31
2.1
3.73
3.55
4.18
5.39
Return on Invested Capital (%)
2.31
4.9
5.3
5.29
2.95
5.91
4.9
4.6
6.74
6.77
5.72
8.21
2.94
3.97
4.09
4.4
4.52
Return on Capital (%)
5.1
12.11
12.85
11.8
5.52
11.16
8.41
7.61
10.67
10.05
8.24
16.69
7.52
10.64
11.25
12.02
8.08
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
May'24
Aug'24
Feb'25
ST Debt
9,721
9,599
- -
LT Borrowings
12,986
13,293
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
- -
Market Capitalization
12,323
11,638
- -

Working Capital

FRC

•

in mil. unless spec.
May'24
Aug'24
Feb'25
Total Current Assets
21,901
22,095
- -
Cash, Cash Equivalents & STI
11,489
12,173
- -
Accounts Receivable, Net
2,777
2,812
2,769
Inventories
6,489
5,982
- -
Total Current Liabilities
17,240
17,622
17,027
Payables & Accruals
- -
- -
- -
ST Debt
9,721
9,599
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.22%
8%
8.9%
Free Cash Flow
-57.41%
-36.02%
-6.15%
Net Income, GAAP
17.62%
29.87%
15.69%
Sales/Revenue/Turnover
9.12%
16.32%
8.18%
Total Cash Common Dividend
15.97%
5.61%
3.73%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6,787
7,756
7,801
7,841
30,185
2025
- -
- -
- -
- -
32,655
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22.8
- -
- -
- -
89.2
2025
- -
- -
- -
- -
102.98
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
29.84
2025
- -
- -
- -
- -
30.88
2026
- -
- -
- -
- -
- -
Similar Companies
Asahimatsu Foods Co., Ltd. (2911.T)
PT Morenzo Abadi Perkasa Tbk (ENZO.JK)
JBS S.A. (JBSAY)
Tarczynski S.A. (TAR.WA)
PT Mahkota Group Tbk (MGRO.JK)
Dongwon F&B Co., Ltd. (049770.KS)
Business
AFC-HD AMS Life Science Co., Ltd. is a Japan-based company primarily engaged in healthcare and pharmaceutical businesses, founded in 1969 and headquartered in Shizuoka City. The company manufactures, sells, and supplies a broad range of products including OEM health foods such as tablets, capsules, granules, soft drinks, and jelly; cosmetics; Chinese herbal medicines; general medicines; ethical drugs; over-the-counter drugs; and generic drugs. It operates through two main segments: Healthcare, focused on health foods and cosmetics production and OEM services, and Pharmaceutical, engaged in ethical and generic drug manufacturing and sales. The company also manages restaurant operations via subsidiaries. Recent strategic developments include partnerships for innovative product development, such as with Japan Preventive Medical Laboratory Co., Ltd., continuous strengthening of OEM capabilities to meet diverse customer needs, and expansion in the health information program sector, encompassing health magazines and related media. AFC-HD AMS Life Science has also made notable operational advancements such as maintaining GMP certification for its manufacturing plants and securing a capital and business alliance with Takara Holdings Inc., alongside acquiring retail chains like Moriya Co. Ltd to broaden market reach. The company’s multifaceted portfolio enables it to serve a comprehensive health and wellness market domestically and internationally with a focus on quality control and research-driven product innovation.